Researchers report on six patients with severe atopic dermatitis (AD) who experienced incomplete relief with dupilumab, the standard targeted treatment for AD. They added a JAK-inhibitor as short-term rescue therapy, which showed significant improvement in disease control without adverse effects.
Read more at the Journal of the American Academy of Dermatology Case Reports.